Nutritional Status and Its Association With Radiation-Induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma During Radiotherapy: A Prospective Study

Background and Aims: Malnutrition is a concern in patients with nasopharyngeal carcinoma (NPC) during chemoradiotherapy (CRT)/radiotherapy (RT), which is considered to be related with radiation–induced oral mucositis (ROM). The study aimed to evaluate the nutritional status of NPC patients during RT and investigate its association with ROM.

Methods: A prospective study was conducted in NPC patients. Patients were divided into three subgroups (mild, moderate, and severe groups) based on the duration of severe ROM (≥ grade 3). Body weight, body mass index (BMI), albumin, prealbumin, NRS2002, and ROM grade were assessed on a weekly basis before and during CRT/RT. The statistical analysis was performed in the overall group and between three subgroups.

Results: A total of 176 patients were included. In the overall group, body weight and BMI kept decreasing since week 1 of RT, and NRS2002 score and ROM grade increased (p < 0.001). NRS2002 score and prealbumin levels were significantly different between each subgroup (p ≤ 0.046). Significant differences were observed in the proportion of patients receiving enteral nutrition, duration of parenteral nutrition, and total calories provided by nutritional support among three subgroups (p = 0.045–0.001).

Conclusions: Malnutrition occurred early in NPC patients and worsened continuously during RT. ROM was strongly associated with nutritional status. Nutritional support should be provided at the start of RT, especially in patients at high-risk of severe ROM.

Introduction

Nasopharyngeal carcinoma (NPC), an epithelial cell cancer in the nasopharynx, is a rare malignancy (1, 2). Even though the annual global incidence is 1.2 per 100,000 individuals, NPC represents a health burden in Southern China, Southeastern Asia, and Southern Africa with more than 70% of new cases distributed in these areas (1). According to the guidelines established by the National Comprehensive Cancer Network (NCCN), the standard treatment consists of CRT with/without neoadjuvant chemotherapy, which is dependent on the cancer stage and physical condition of the patient (2, 3). With novel RT technology, intensity-modulated radiotherapy (IMRT), and helical tomotherapy (TOMO), CRT treatment provides 80% of 5–year survival rate and 90% of 3–year locoregional control rate (4, 5).

Although the prognosis of NPC is good, certain acute side effects of RT may affect the course of treatment, including xerostomia, skin reactions, hearing loss, pharyngitis, vomiting, and radiation-induced oral mucositis (ROM) (5–7). ROM, which may lead to serious consequences (8, 9), occurs in over 90% of patients with head and neck cancer (HNC) and almost all NPC patients, 34% to 66% of whom develop severe ROM (≥ grade 3) (8, 10, 11). In severe ROM, patients experience ulceration, necrosis, severe oral pain, and malnutrition due to difficulties in food intake (10, 12, 13). In mild ROM (≤ grade 2), 38% of patients still experience difficulties with food intake (8).

The nutritional status of patients will deteriorate, which can lead to severe weight loss, poor physical condition, and treatment interruption (14–16). However, there is no direct evidence on the extent of ROM’s impact on nutritional status. This prospective study investigated the nutritional status of NPC patients during RT and its association with ROM. We assessed body weight, BMI, serum albumin, prealbumin, NRS2002 score, and ROM grade on a weekly basis according CTCAE 4.0 (Grade 1-5, Supplemental Table 1) (17). Data of this study were acquired from a multi–centric randomized controlled trial (RCT; NCT03720340).

Material and Methods

Study Population

This study was conducted in five medical centers. The inclusion criteria: 1) NPC patients with confirmed pathogenesis; 2) cancer stages I–IVB according to the 8th version of the American Joint Committee on Cancer; 3) patients between the ages of 18 and 75 years; 4) performance status of 0 or 1 based on the Eastern Cooperative Oncology Group; 5) no bone marrow, renal, hepatic disorders; 6) patients willing to participate in the study and sign an informed consent. The exclusion criteria were the following, 1) treatment with palliative intent; 2) patients with previous malignancy; 3) pregnancy or lactation; 4) patients who underwent radiotherapy, chemotherapy, or surgery (except biopsy operation) for primary tumors or nodes; 5) patients of oral mucositis or senile dry stomatitis before treatment; or 6) presence of severe comorbidities. 7) chemotherapy with fluorouracil drugs; allergies to recombinant human interleukin-11.

Treatment Plan

IMRT or TOMO plan was implemented before RT as previously reported (18, 19). Radiation was delivered five times a week from Monday through Friday for six to seven weeks (an average of six and a half weeks). Platinum-based drugs were used in neoadjuvant and concurrent chemotherapy. The most commonly used regimen was 3 cycles of neoadjuvant chemotherapy and 0 to 2 cycles of concurrent chemotherapy. Some patients received 3 to 8 cycles of concurrent nimotuzumab (200 mg/week; 7 cycles for most patients).

Nutrition Supplement

As data of this study were acquired from an RCT, there were no standard guidelines or procedures for nutritional support. Nutritional support (commercial products) was provided based on the nutritional status of the patient and consisted of an enteral nutrition supplement (oral nutrition administered and enteral tube feeding) and a parenteral nutrition supplement.

Data Collection

Clinical data were collected before (T0) and at the end of each week during RT (T1–T6). Clinical data included patient characteristics (age, sex, Barthel index score, tumor stage, smoking history, alcohol consumption history, and treatment plan, etc), nutritional factors (body weight, BMI, serum albumin, and prealbumin), nutritional support (number of patients receiving enteral and parenteral nutrition, duration of parenteral nutrition, and total calories of enteral and parenteral nutrition supplements).

A trained clinical research coordinator (CRC) evaluated the nutrition status of every patient according to NRS2002 before and during RT (20). Additionally, ROM grade was assessed according to CTCAE 4.0 (Grade 1-5, Supplemental Table 1) (17).

Statistical Analysis

We calculated mean and standard division (SD) for continuous variables and frequency for categorical variables. We used paired Student’s t-test to compare differences between T0 and T1–T6 in NRS2002 score, ROM grade, body weight ratio (BWR, ratio of body weight at T1-T6 to T0), BMI, serum albumin, and prealbumin. Variance analysis (ANOVA) was used to assess differences in NRS2002 score, ROM grade, BWR, BMI, serum albumin, prealbumin, duration of parenteral nutrition supplement, starting time of enteral and parenteral nutrition supplement, and total calories of enteral and parenteral nutrition. Chi-square test was used in the analysis of the proportion of patients receiving general nutrition support, enteral nutrition, and parenteral nutrition. Statistically significance was set at p < 0.05. SPSS software version 24.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analyses.

Results

Patient Characteristics

The RCT involved 272 patients up to Jan 2020. In this study, 176 patients with comprehensive data were included. The basic clinical characteristics are presented in Table 1. There were 122 (69.3%) males and 54 (30.7%) female patients with a median age of 51 years. Body weight and BMI before RT were 65.99 ± 11.00 kg and 23.98 ± 3.23, respectively. A total of 167 (94.9%) patients received neoadjuvant chemotherapy, 157 (89.2%) patients received concurrent chemotherapy, and 118 (67.0%) received nimotuzumab. The most common radiation technology was IMRT (69.9%), followed by TOMO (30.1%).

TABLE 1

Table 1 Patient characteristics.

Nutritional Status and Oral Condition in the Overall Group During RT

In the overall group, BWR and BMI decreased since the beginning of RT (Figures 1A, B) and the differences remained significant since T1 (p < 0.001; Table 2). NRS2002 score increased from the start of treatment (Figure 1C), and the differences in the scores were statistically significant from T1 (p < 0.001; Table 2). A similar trend was obtained in ROM grade, which reached its maximum value at T3 and plateaued thereafter (Figure 1D; Table 2).

FIGURE 1

Figure 1 Changes in clinical factors, BWR (A), BMI (B), NRS2002 score (C), ROM grade (D), albumin (E), and prealbumin (F), of all patients during CRT/RT treatment.

TABLE 2

Table 2 Changes in clinical factors of all patients during chemoradiotherapy (CRT)/radiotherapy (RT) treatment and comparison between T0 and T1–T6 in NRS2002 score, ROM grade, BWR, BMI, albumin, and prealbumin.

In general, the change trend of albumin level was downward, but there was a rise at T2 and T3 (Figure 1E). And the differences were significant since T4 (p < 0.001; Table 2). Prealbumin levels were higher at T1 than at T0 (p < 0.001; Table 2 and Figure 1F) and subsequently decreased with a slight increase at T5. Prealbumin level became significant lower since T3 compared with T0 (p < 0.001, Table 2).

Association Between Nutritional Status and ROM

To evaluate a possible association between ROM and nutritional status, patients were divided into three subgroups based on the duration of severe ROM (≥ grade 3). Patients without severe ROM were classified as the mild group, and those with severe ROM for 1–2 or ≥ 3 weeks were classified as moderate and severe groups, respectively. There were 67 (38.1%) patients were in the mild group, 75 (42.6%) were in the moderate group, and 34 (19.3%) were in the severe group. Table 3 and Figure 2D showed that ROM grade diverged since T2 between each subgroup (p ≤ 0.020).

TABLE 3

Table 3 Comparison between mild, moderate, and severe groups in NRS2002 score and ROM grade at T0–T6 during chemoradiotherapy (CRT)/radiotherapy (RT) treatment.

FIGURE 2

Figure 2 Changes in clinical factors, BWR (A), BMI (B), NRS2002 score (C), ROM grade (D), albumin (E), and prealbumin (F), in mild, moderate, and severe groups during CRT/RT treatment.

BWR and BMI decreased, while albumin levels increased at certain time points in the three subgroups (Figures 2A, B, E). There were no significant differences in BWR, BMI, or albumin between the subgroups at each time point (p > 0.05), except for albumin levels between the mild and moderate groups at T6 (p = 0.035; Tables 4 and 5).

TABLE 4

Table 4 Comparison between mild, moderate, and severe groups in BWR and BMI at T0–T6 during CRT/RT treatment.

TABLE 5

Table 5 Comparison between mild, moderate, and severe groups in albumin and prealbumin levels at T0–T6 during chemoradiotherapy (CRT)/radiotherapy (RT) treatment.

NRS2002 scores increased as treatment continued (Figure 2C), and differences became significant between the mild and moderate groups since T3 (p ≤ 0.001; Table 3), and between moderate and severe groups since T2 (p = 0.005–0.046). Differences were significant at each time point between the mild and severe groups (p ≤ 0.041).

Figure 2F showed that the three subgroups had nearly the same prealbumin levels before RT (T0). However, in the mild group, prealbumin levels increased at T1 and declined subsequently with a slight rise at T5, while it decreased in the severe group since the start of treatment. In the moderate group, prealbumin levels were similar to those of the mild group and decreased at T3-T4, then increased to an intermediate level since T5. There were significant differences in prealbumin levels between the mild and severe groups since T1 (p = 0.002–0.02; Table 5), between the mild and moderate groups at T4 (p = 0.040), and between the moderate and severe groups at T1-T3 (p = 0.009–0.039).

Since NRS2002 score and prealbumin levels were significantly different between each subgroup with One Way ANOVA, we further used Repeated Measures ANOVA to verify it, which showed that the differences remained significant (p < 0.001, p = 0.041; Supplemental Tables 2, 3).

Benefits of Nutritional Support

Among three subgroups, there were no significant differences in the proportion of patients receiving general nutritional support and parenteral nutrition (p = 0.055, p = 0.085; Table 6). The difference in the proportion of patients receiving enteral nutrition was significant (p = 0.045).

TABLE 6

Table 6 Comparison between mild, moderate, and severe groups in general nutritional support, enteral nutrition, parenteral nutrition, duration of parenteral nutrition, starting time of enteral and parenteral nutrition, and total calories provided by nutritional support at T0–T6 during chemoradiotherapy (CRT)/radiotherapy (RT) treatment.

The starting time of enteral nutrition was approximately week 3 in the three subgroups (p = 0.400). Although not statistically different, the starting time of parenteral nutrition was week 4 in the mild and moderate groups, and week 3 in the severe group (p = 0.055). The duration of parenteral nutrition was the longest in the severe group, and the total calories provided by nutritional support increased as ROM severity worsened (p = 0.025; p = 0.001).

Discussion

Malnutrition is a common problem in NPC patients during RT as a result of gastrointestinal reactions to concurrent chemotherapy, xerostomia, psychological distress, and ROM (21–24). Severe weight loss and poor physical condition due to malnutrition may lead to CRT interruptions, poor treatment tolerance, and abandonment of concurrent chemotherapy, which eventually impact prognosis (25, 26). Numerous trials have reported that certain nutritional factors are correlated with disease survival outcomes and distant metastasis in various malignancies including NPC, which highlight the significance of adequate nutritional status in NPC patients during treatment (27–33).

Previous studies have reported the deteriorating nutritional status of NPC patients during RT (15, 16, 34–39). However, most studies only reported the weight loss after treatment, and nutritional status was evaluated only before and at the end of RT, as opposed to during treatment. In a prospective study, the median weight loss during RT was 6.9 kg (2.1–12.6 kg), representing 3.5% to 16.4% weight loss (36). Jager-Wittenaar reported the average weight loss was 3.6 kg, which was 4.7% of pre-treatment body weight (38). In the Nourissat’s study, even though the average weight loss decreased to 2.2 kg with only 25% of HNC patients reporting severe weight loss (≥ 5%), researchers concluded that the rate was likely underestimated (40). In our study, mean weight loss was 6% of pre-treatment body weight at the end of RT, and we further found body weight and BMI significantly decreased since T1 and continued decreasing throughout the entire RT process, and the percentage of average weight loss was already 5% at T5. Actually, weight loss had already started prior to RT (36, 41, 42), revealing the presence of malnutrition before RT was initiated. The reason may be attributed to metabolic and endocrine changes and hypercatabolism caused by the responsiveness to chemotherapy, which make malnutrition cannot be fully reversed by conventional nutritional support (43). In addition, body weight is not a sensitive nutrition parameter over a short period of time (44, 45). Like body weight and BMI, the change of NRS2002 score also revealed the deteriorating nutritional status of patients, which further supported the conclusion that it was quite necessary to provide nutritional support and education at the start of RT.

Albumin is commonly used as a nutritional marker of protein-energy in clinical practice, however, we found prealbumin that responded quickly to nutritional interventions was more sensitive and suitable for NPC patients (46–48). Although a significant decrease in prealbumin levels was observed after RT compared with baseline like previous studies (15, 39), we found an increase at T1 and T5. Since all patients received nutrition education before treatment and the nutritional support had become more frequently in our cancer center, we speculated that prealbumin levels increased at T1 due to early nutrition education and at T5 due to nutritional support and re-education, which again proved the importance of early nutritional support.

The association between nutritional status and ROM was investigated. To our knowledge, this is the first prospective observational study that specifically worked on this. We innovatively divided patients into three subgroups: mild, moderate and severe groups. The results of NRS2002 scores and prealbumin levels showed that there was a strong association between nutritional status and ROM, indicating that malnutrition was largely caused by ROM. What beyond our expectation is that we found malnutrition was not only the consequence of ROM. As presented in Table 3, the difference between mild and severe group in NRS2002 score at T0 was significant, which indicating that malnutrition was very likely to be a risk factor to ROM. Although not significant, the prealbumin level of mild and moderate groups was higher than severe group at T0 as well. Our previous study also found that body weight loss ≥ 5% was a related risk factor to severe ROM (19). Two other studies conducted in oral cavity cancer patients found that lower BMI was significantly related with severe ROM (49, 50). The underlying mechanism might be that malnutrition could interfere with mucosal regeneration due to decreased cellular migration and renewal resulting from poor nutrition status (51). In conclusion, nutritional support should be more frequent and earlier not only to reverse malnutrition due to ROM but also reduce the risk of developing severe ROM.

We further compared nutritional support among the three subgroups, and found significant differences in the proportion of patients receiving enteral nutrition, duration of parenteral nutrition, and total calories provided by nutritional support. However, the severe group still had the worst nutritional status, which meant that nutritional support should be provided earlier than usual.

The study had several limitations. Although the sample size was not small, we excluded 96 patients mainly due to lack of comprehensive data (prealbumin and albumin test, data on nutritional support, etc), which might cause bias. As mentioned above, there were no standard guidelines or procedures for nutritional support, the conclusion of differences in nutritional support among three subgroups was not that reliable.

Conclusion

Malnutrition is very common in NPC patients and occurs earlier than usually expected during RT. ROM is strongly associated with nutritional status, which might be bidirectional. Therefore, adequate nutritional support should be provided to all NPC patients at the start of RT, especially those at high-risk of severe ROM. Thus, further studies are needed to explore approaches to identify high-risk patients.

Data Availability Statement

The data analyzed in this study is subject to the following licenses/restrictions: this paper was generated from a part of the datasets, which will be used in other papers that focused on different research topic. Thus, the datasets were not publicly available. Requests to access these datasets should be directed to Y2hlbnl5QHpqY2Mub3JnLmNu.

Ethics Statement

The study was approved by five medical centers, Zhejiang Cancer Hospital (IRB-2018-180), Sun Yat-sen University Cancer Center (B2019-069-01), Affiliated Cancer Hospital of Zhengzhou University (2019268), Affiliated Hospital of Guangdong Medical University (PJ2019-063), and The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University (YX-P-2019-059-01). The patients provided their written informed consent to participate in this study.

Author Contributions

YC and LL designed the research. ZS, ZZ, and BY disposal data. JC and WS performed the statistical analysis; Other authors made efforts to recruit patients. All authors contributed to the article and approved the submitted version.

Funding

The study received financial support from Qilu Pharmaceutical Co., Ltd.

Conflict of Interest

Authors JC and WS were employed by the company Hangzhou YITU Healthcare Technology Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors declare that this study received funding from Qilu Pharmaceutical Co., Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Acknowledgments

We wish to express our sincere appreciation to all patients and medical staffs participating in this study for the great effort during this tough period.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.594687/full#supplementary-material

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127:2893–917. doi: 10.1002/ijc.25516

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (2019) 394:64–80. doi: 10.1016/s0140-6736(19)30956-0

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 20:2038–44. doi: 10.1200/jco.2002.08.149

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, et al. Evolution of treatment for nasopharyngeal cancer–success and setback in the intensity-modulated radiotherapy era. Radiother Oncol (2014) 110:377–84. doi: 10.1016/j.radonc.2014.02.003

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol (2005) 23:6966–75. doi: 10.1200/jco.2004.00.7542

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol (2012) 104:286–93. doi: 10.1016/j.radonc.2012.08.013

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys (2012) 82:327–33. doi: 10.1016/j.ijrobp.2010.09.011

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys (2007) 68:1110–20. doi: 10.1016/j.ijrobp.2007.01.053

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer (2004) 100:1995–2025. doi: 10.1002/cncr.20162

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer (2014) 120:1453–61. doi: 10.1002/cncr.28592

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer (2006) 106:329–36. doi: 10.1002/cncr.21622

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol (2015) 26 Suppl 5:v139–51. doi: 10.1093/annonc/mdv202

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Mallick S, Benson R, Rath GK. Radiation induced oral mucositis: a review of current literature on prevention and management. Eur Arch Otorhinolaryngol (2016) 273:2285–93. doi: 10.1007/s00405-015-3694-6

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Li G, Gao J, Liu ZG, Tao YL, Xu BQ, Tu ZW, et al. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution. Head Neck (2014) 36:660–6. doi: 10.1002/hed.23357

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Meng L, Wei J, Ji R, Wang B, Xu X, Xin Y, et al. Effect of Early Nutrition Intervention on Advanced Nasopharyngeal Carcinoma Patients Receiving Chemoradiotherapy. J Cancer (2019) 10:3650–6. doi: 10.7150/jca.33475

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Xu Y, Guo Q, Lin J, Chen B, Wen J, Lu T, et al. Benefit of percutaneous endoscopic gastrostomy in patients undergoing definitive chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Onco Targets Ther (2016) 9:6835–41. doi: 10.2147/ott.S117676

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute (2009). Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.

Google Scholar

18. Li K, Yang L, Hu QY, Chen XZ, Chen M, Chen Y. Oral Mucosa Dose Parameters Predicting Grade ≥3 Acute Toxicity in Locally Advanced Nasopharyngeal Carcinoma Patients Treated With Concurrent Intensity-Modulated Radiation Therapy and Chemotherapy: An Independent Validation Study Comparing Oral Cavity versus Mucosal Surface Contouring Techniques. Transl Oncol (2017) 10:752–9. doi: 10.1016/j.tranon.2017.06.011

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Li K, Yang L, Xin P, Chen Y, Hu QY, Chen XZ, et al. Impact of dose volume parameters and clinical factors on acute radiation oral mucositis for locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemoradiotherapy. Oral Oncol (2017) 72:32–7. doi: 10.1016/j.oraloncology.2017.06.026

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Poulia KA, Klek S, Doundoulakis I, Bouras E, Karayiannis D, Baschali A, et al. The two most popular malnutrition screening tools in the light of the new ESPEN consensus definition of the diagnostic criteria for malnutrition. Clin Nutr (2017) 36:1130–5. doi: 10.1016/j.clnu.2016.07.014

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Gobbo M, Ottaviani G, Perinetti G, Ciriello F, Beorchia A, Giacca M, et al. Evaluation of nutritional status in head and neck radio-treated patients affected by oral mucositis: efficacy of class IV laser therapy. Support Care Cancer (2014) 22:1851–6. doi: 10.1007/s00520-014-2155-x

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Zhu C, Wang B, Gao Y, Ma X. Prevalence and relationship of malnutrition and distress in patients with Cancer using questionnaires. BMC Cancer (2018) 18:1272. doi: 10.1186/s12885-018-5176-x

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Caillet P, Liuu E, Raynaud Simon A, Bonnefoy M, Guerin O, Berrut G, et al. Association between cachexia, chemotherapy and outcomes in older cancer patients: A systematic review. Clin Nutr (2017) 36:1473–82. doi: 10.1016/j.clnu.2016.12.003

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Chen YJ, Chen SC, Wang CP, Fang YY, Lee YH, Lou PJ, et al. Trismus, xerostomia and nutrition status in nasopharyngeal carcinoma survivors treated with radiation. Eur J Cancer Care (Engl) (2016) 25:440–8. doi: 10.1111/ecc.12270

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313. Cancer (1992) 69:2744–8. doi: 10.1002/1097-0142(19920601)69:11<2744::aid-cncr2820691119>3.0.co;2-u

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Kwong DL, Sham JS, Chua DT, Choy DT, Au GK, Wu PM. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (1997) 39:703–10. doi: 10.1016/s0360-3016(97)00339-8

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Feng JF, Chen QX. Significance of the prognostic nutritional index in patients with esophageal squamous cell carcinoma. Ther Clin Risk Manag (2014) 10:1–7. doi: 10.2147/tcrm.S56159

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg (2011) 98:268–74. doi: 10.1002/bjs.7305

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Nozoe T, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, Ezaki T. Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. Surg Today (2010) 40:440–3. doi: 10.1007/s00595-009-4065-y

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer (2012) 106:1439–45. doi: 10.1038/bjc.2012.92

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Yang L, Xia L, Wang Y, Hong S, Chen H, Liang S, et al. Low Prognostic Nutritional Index (PNI) Predicts Unfavorable Distant Metastasis-Free Survival in Nasopharyngeal Carcinoma: A Propensity Score-Matched Analysis. PloS One (2016) 11:e0158853. doi: 10.1371/journal.pone.0158853

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Du XJ, Tang LL, Mao YP, Guo R, Sun Y, Lin AH, et al. Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. J Transl Med (2015) 13:364. doi: 10.1186/s12967-015-0729-0

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Peng H, Chen BB, Tang LL, Chen L, Li WF, Zhang Y, et al. Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A large-scale cohort study. Cancer Sci (2018) 109:1909–19. doi: 10.1111/cas.13603

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Ding H, Dou S, Ling Y, Zhu G, Wang Q, Wu Y, et al. Longitudinal Body Composition Changes and the Importance of Fat-Free Mass Index in Locally Advanced Nasopharyngeal Carcinoma Patients Undergoing Concurrent Chemoradiotherapy. Integr Cancer Ther (2018) 17:1125–31. doi: 10.1177/1534735418807969

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Huang JF, Sun RJ, Jiang WJ, Wu P, Zhang L, Xu MQ, et al. Systematic nutrition management for locally advanced nasopharyngeal carcinoma patients undergoing radiotherapy. Onco Targets Ther (2019) 12:8379–86. doi: 10.2147/ott.S213789

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Qiu C, Yang N, Tian G, Liu H. Weight loss during radiotherapy for nasopharyngeal carcinoma: a prospective study from northern China. Nutr Cancer (2011) 63:873–9. doi: 10.1080/01635581.2011.582223

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Arribas L, Hurtós L, Taberna M, Peiró I, Vilajosana E, Lozano A, et al. Nutritional changes in patients with locally advanced head and neck cancer during treatment. Oral Oncol (2017) 71:67–74. doi: 10.1016/j.oraloncology.2017.06.003

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Jager-Wittenaar H, Dijkstra PU, Vissink A, Langendijk JA, van der Laan BF, Pruim J, et al. Changes in nutritional status and dietary intake during and after head and neck cancer treatment. Head Neck (2011) 33:863–70. doi: 10.1002/hed.21546

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Hong JS, Wu LH, Su L, Zhang HR, Lv WL, Zhang WJ, et al. Effect of chemoradiotherapy on nutrition status of patients with nasopharyngeal cancer. Nutr Cancer (2016) 68:63–9. doi: 10.1080/01635581.2016.1115099

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Nourissat A, Bairati I, Samson E, Fortin A, Gélinas M, Nabid A, et al. Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer. Cancer (2010) 116:2275–83. doi: 10.1002/cncr.25041

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Beaver ME, Matheny KE, Roberts DB, Myers JN. Predictors of weight loss during radiation therapy. Otolaryngol Head Neck Surg (2001) 125:645–8. doi: 10.1067/mhn.2001.120428

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Jager-Wittenaar H, Dijkstra PU, Vissink A, van der Laan BF, van Oort RP, Roodenburg JL. Critical weight loss in head and neck cancer–prevalence and risk factors at diagnosis: an explorative study. Support Care Cancer (2007) 15:1045–50. doi: 10.1007/s00520-006-0212-9

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 12:489–95. doi: 10.1016/s1470-2045(10)70218-7

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Waitzberg DL, Correia MI. Nutritional assessment in the hospitalized patient. Curr Opin Clin Nutr Metab Care (2003) 6:531–8. doi: 10.1097/00075197-200309000-00006

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Malecka-Massalska T, Smolen A, Zubrzycki J, Lupa-Zatwarnicka K, Morshed K. Bioimpedance vector pattern in head and neck squamous cell carcinoma. J Physiol Pharmacol (2012) 63:101–4.

PubMed Abstract | Google Scholar

46. Guerra LT, Rosa AR, Romani RF, Gurski RR, Schirmer CC, Kruel CD. Serum transferrin and serum prealbumin as markers of response to nutritional support in patients with esophageal cancer. Nutr Hosp (2009) 24:241–2.

PubMed Abstract | Google Scholar

47. Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician (2002) 65:1575–8.

PubMed Abstract | Google Scholar

48. Unal D, Orhan O, Eroglu C, Kaplan B. Prealbumin is a more sensitive marker than albumin to assess the nutritional status in patients undergoing radiotherapy for head and neck cancer. Contemp Oncol (Pozn) (2013) 17:276–80. doi: 10.5114/wo.2013.35281

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Saito N, Imai Y, Muto T, Sairenchi T. Low body mass index as a risk factor of moderate to severe oral mucositis in oral cancer patients with radiotherapy. Support Care Cancer (2012) 20:3373–7. doi: 10.1007/s00520-012-1620-7

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Chen SC, Lai YH, Huang BS, Lin CY, Fan KH, Chang JT. Changes and predictors of radiation-induced oral mucositis in patients with oral cavity cancer during active treatment. Eur J Oncol Nurs (2015) 19:214–9. doi: 10.1016/j.ejon.2014.12.001

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Raber-Durlacher JE. Current practices for management of oral mucositis in cancer patients. Support Care Cancer (1999) 7:71–4. doi: 10.1007/s005200050229

PubMed Abstract | CrossRef Full Text | Google Scholar